T cells are an important part of the immune system, playing a critical role in the response to infected, foreign or altered cells.
Cambridge Innovation Capital is a leading Series A investor in the Cambridge ecosystem.
Team
Insights
Purpose
Commitment
Our People
Companies
News & insights
Information
Legal
News & insights
Information
Legal
Cambridge Innovation Capital is a leading Series A investor in the Cambridge ecosystem.
Team
Insights
Purpose
Commitment
Our People
Companies
News & insights
Information
Legal
News & insights
Information
Legal
Location: United Kingdom, England, Cambridge
Employees: 51-200
Total raised: $59.63M
Investors 2
| Date | Name | Website |
| - | F-Prime Ca... | fprimecapi... |
| 18.05.2023 | Cambridge ... | cic.vc |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.11.2023 | Series A | $59.63M | - |
Mentions in press and media 5
| Date | Title | Description |
| 19.03.2024 | The World’s Most Innovative Companies of 2024 | - |
| 21.11.2023 | Parkwalk supports ‘Founders at the University of Cambridge’ pre-seed accelerator | Along with 100 experts from Graphcore, Arm, Google and Stripe, we are proud to support the Founders at the University of Cambridge, with Cambridge Enterprise, aiding the next generation of start-ups. This new initiative is the first pre-see... |
| 16.11.2023 | T-Therapeutics Raises £48M in Series A Financing | T-Therapeutics, a Cambridge, UK-based biotechnology company developing TCR therapeutics, raised $48M in Series A funding. The round was led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital (CIC) wi... |
| 15.11.2023 | T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatment | - |
| - | T-Therapeutics | “Home - T-Therapeutics” |